首页> 美国卫生研究院文献>Frontiers in Neurology >Assessing the Safety of Craniotomy for Resection of Primary Central Nervous System Lymphoma: A Nationwide Inpatient Sample Analysis
【2h】

Assessing the Safety of Craniotomy for Resection of Primary Central Nervous System Lymphoma: A Nationwide Inpatient Sample Analysis

机译:评估开颅手术切除原发性中枢神经系统淋巴瘤的安全性:全国住院患者样本分析

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundUnlike many other central nervous system (CNS) tumors, the surgical management of primary central nervous system lymphomas (PCNSL) is traditionally limited by diagnostic biopsy. Studies that predate the use of modern neurosurgical techniques have reported a prohibitive operative morbidity for this surgery. These early experiences have dictated the non-surgical management of PCNSL, whereas resection for cytoreduction is a mainstay of treatment in other CNS malignancies. Recent studies have suggested that craniotomy with the goal of cytoreduction might be associated with a favorable overall and progression-free survival for some patients with PCNSL. To challenge the traditional non-surgical paradigm, it is essential to first investigate the safety of resection for PCNSL.
机译:背景技术与许多其他中枢神经系统(CNS)肿瘤不同,原发性中枢神经系统淋巴瘤(PCNSL)的外科治疗传统上受诊断性活检的限制。在使用现代神经外科技术之前的研究已经报告了该手术的手术并发症。这些早期经验决定了PCNSL的非手术治疗,而切除细胞的方法是其他CNS恶性肿瘤的主要治疗手段。最近的研究表明,以减少细胞数量为目标的开颅手术可能与某些PCNSL患者的总体生存期和无进展生存期有关。为了挑战传统的非手术范例,必须首先研究PCNSL切除术的安全性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号